builderall

CONFERENCE INFORMATION

CONFERENCE DESCRIPTION

The 2026 Masters in Therapeutic Oncology Summit – Gastrointestinal Edition (MaTOS | GI Edition) is an advanced, CME-accredited forum designed to address identified practice gaps, share evolving clinical evidence, and elevate the standard of care for gastrointestinal cancers. Bringing together leading experts, investigators, and multidisciplinary care teams, the summit provides an immersive educational experience grounded in clinical science, interactive dialogue, and real-world applicability. Covering a broad spectrum of GI malignancies—including esophageal, gastric, hepatocellular, pancreatic, cholangiocarcinoma, colorectal, and rare tumors—the summit will focus on:

Attendees will benefit from a dynamic mix of expert-led panels, moderated debates, roundtable case discussions, and keynote addresses. These sessions will provide practical guidance for complex clinical scenarios, illuminate future directions in GI oncology, and facilitate implementation of the latest diagnostic and therapeutic advances in day-to-day oncology practice.

MaTOS | GI Edition fosters a culture of multidisciplinary exchange and critical reflection. It will empower healthcare professionals to adopt novel approaches, improve clinical decision-making, and ultimately enhance patient-centered outcomes across the continuum of gastrointestinal cancer care.

LEARNER OBJECTIVES

Upon conclusion of this summit, participants will be able to:

  • Apply evolving standards of care in the treatment of GI cancers by integrating current evidence and expert consensus across diverse disease states including esophageal, gastric, pancreatic, hepatocellular, cholangiocarcinoma, and colorectal cancers.

  • Evaluate the role of surgery, radiation, and systemic therapy in curative, borderline, and advanced settings, with emphasis on case-based application and disease-specific considerations.

  • Incorporate molecular profiling and liquid biopsy techniques into diagnostic workflows, minimal residual disease (MRD) monitoring, and therapeutic decision-making.

  • Differentiate the clinical utility of immunotherapies and targeted therapies—including checkpoint inhibitors, FGFR inhibitors, HER2-targeted agents, and novel combinations—in early-stage and advanced GI malignancies.

  • Critically analyze real-world case discussions to develop personalized, evidence-based treatment plans for special patient populations, including those with comorbidities, germline mutations, or rare tumor types.

  • Discuss emerging therapies and future directions in GI oncology, including novel agents in development, tumor treating fields (TTFs), and precision treatment strategies projected for the next decade.

  • Interpret controversies and clinical trial evidence through moderated debates and expert panels, fostering nuanced understanding of differing approaches such as FLOT vs CROSS or the role of radiation in pancreatic and esophageal cancers.

  • Identify strategies to optimize multidisciplinary collaboration among oncologists, surgeons, radiologists, pathologists, and palliative care providers to enhance care delivery in complex GI oncology scenarios.